The paper provides the rationale for these recommendations, which are based on analyses of data from the TRACT trial.
BMJ Open2018;8:e020423. doi:10.1136/bmjopen-2017-02042
EC has been increasingly used in the evaluation of maternal and child health programmes.12–15 For instance, Nesbitt et al compared crude coverage and EC of pregnant women with facility-based obstetric services in Ghana and estimated that alth...ough 68% of the women studied had service access only 18% received high-quality care provided by a skilled birth attendant.16 Similarly, by comparing EC of young children receiving Strengths and limitation of this study. Using multiple data sources (direct observation, vignettes, facility inventories) this study comprehensively assessed under 5-year-old child service
performance of first-line health facilities. We conducted this study in around 500 primary-level health facilities and within 7000 households
across six regions in Burkina Faso.
more
This report provides a review and analysis of the research landscape for three diseases – Chagas disease, human African trypanosomiasis and leishmaniasis – that disproportionately afflict poor and remote populations with limited access to health services. It represents the work of the disease re...ference group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis (DRG3) which was established to identify key research priorities through review of research evidence and input from stakeholders' consultations.
more
Case Management; Guide for Tutors
2nd edition. The interagency field handbook on malaria control was developed to set out effective malaria control responses in humanitarian emergencies, particularly during the acute phase when reliance on international humanitarian assistance is greatest. This second edition represents a thorough u...pdating and revision of the first edition. The structure remains similar, but includes an additional chapter on humanitarian coordination. All chapters have been revised to reflect changes in best practices, improvements in technologies, availability of new tools, and changes in WHO recommendations.
more
In Sierra Leone, Health care delivery is organized around a three-tier system i) primary level constituting peripheral health units (community health centers, community health posts, and maternal and child health posts secondary level constituting district hospitals tertiary level comprising region...al and national referral hospitals [Figure 3].
more
PLoS Neglected Tropical diseases August 16, 2021 https://doi.org/10.1371/journal.pntd.0009697
Chagas disease, also known as American trypanosomiasis, is a neglected tropical disease transmitted by triatomine insects, first identified in 1909. Chagas disease affects approximately 6–7 million peop...le globally and is highly prevalent in Latin America where most cases are reported. However, there is increasing evidence that Chagas disease is now an important public health issue outside the “classical” endemic countries due to population migration. Our understanding of Chagas disease, including its pathologies and factors relating to progression, remains to date limited, and is also challenged by lack of diagnosis and highly effective treatment. This systematic review aims to describe studies with Chagas patients receiving antiparasitic treatment. Databases were searched for relevant studies published after 1997, and the results of these searches were screened.
more
PLoS Negl Trop Dis 16(11): e0010885. https://doi.org/10.1371/journal.pntd.0010885
HAT diagnosis in non-endemic countries is rare and can be challenging, but alertness and
surveillance must be maintained to contribute to WHO’s elimination goals. Early detection is
particularly important as it co...nsiderably improves the prognosis.
more
The Lancet Infectious Disease Volume 25, Issue 2e77-e85February 2025
Guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings
Esta nota técnica busca guiar a los programas nacionales de malaria y a las organizaciones implicadas en el apoyo de los esfuerzos para la eliminación de la malaria en la Región de las Américas, a fin de que intensifiquen las acciones políticas/estratégicas e implementen los cambios operativos... necesarios para acelerar la eliminación de P. falciparum como parte de las estrategias nacionales para la eliminación de la malaria. Con tal finalidad, orienta las acciones que deben llevarse a cabo para acelerar la eliminación de P. falciparum en zonas próximas a su eliminación, sin comprometer los esfuerzos unificados de eliminación del paludismo (P. vivax - P. falciparum) y contribuyendo al objetivo final del país de eliminar el paludismo en su conjunto. La aceleración de la eliminación de P. falciparum procura mitigar el riesgo de aparición y propagación de la resistencia a la artemisinina y de la resistencia a los fármacos asociados; acelerar la reducción del número total de casos de paludismo en zonas con una proporción importante de P falciparum; acelerar la eliminación de la malaria (P. vivax y P. falciparum) teniendo en cuenta que P. falciparum es uno de los desencadenantes de las recaídas de P. vivax; desarrollar capacidades en intervenciones para acelerar la eliminación de la malaria a partir de la experiencia de eliminación de P. falciparum, reduciendo el tiempo para alcanzar la eliminación de la malaria; y empoderar a diferentes actores, autoridades de alto nivel, donantes, municipios y otras entidades para la eliminación de la malaria con inspiración en los logros de la eliminación del P. falciparum.
more
All malaria-endemic countries in the Region of the Americas have taken on the challenge of eliminating malaria and have focused their health programs and strategies on that goal. The risk of emergence of artemisinin resistance in the Americas, the characteristics of P. falciparum parasite, and the e...pidemiological evidence of subnational territories experiencing reintroduction of P. falciparum urge for a call to push for P. falciparum elimination as an intermediate goal of the elimination of all malaria human species. Derived from the elimination of P. falciparum, other important results are expected, such as the empowerment of different actors and entities for the elimination of malaria inspired by the achievements of the elimination of P. falciparum, using early victories as a catalyst. This technical note provides guidance on actions to accelerate P. falciparum elimination in areas close to achieving this goal without compromising unified malaria elimination efforts (P. vivax - P. falciparum), while contributing to the country's ultimate goal of eliminating malaria overall. The acceleration of P. falciparum elimination has several goals: mitigating the risk that resistance to artemisinin and associated drugs will emerge and spread; accelerating the reduction in the total number of malaria cases in areas with a significant proportion of P. falciparum; accelerating malaria elimination (both P. vivax and P. falciparum), considering that P. falciparum is one of the triggers of P. vivax relapses; developing capacities in interventions to accelerate malaria elimination by building on the experience of P. falciparum elimination; and empowering different actors, including high-level authorities, donors, municipalities, and other entities involved in malaria elimination, by inspiring them with the achievements of P. falciparum elimination.
more
Malaria in pregnancy is a significant health problem in malaria-endemic areas. It not only causes substantial childhood morbidity and mortality but also increases the risks of adverse events for pregnant women and their developing fetuses. Most of the burden in these areas is due to infection with P...lasmodium falciparum. Artemisinin-based combination therapy (ACT) has been recommended as first-line treatment for uncomplicated P. falciparum malaria in all populations, including pregnant women in their second and third trimesters, since 2006. However, for women in their first trimester of pregnancy, WHO recommended as first-line treatment a combination of quinine and clindamycin.
Based on a review of the evidence conducted in 2022, WHO now recommends artemether–lumefantrine, the ACT with the most human safety data available, as the preferred treatment for uncomplicated P. falciparum malaria in the first trimester of pregnancy. This document presents all relevant evidence on the effects and safety in early pregnancy of artemisinins and partner medicines used in ACTs from both studies in experimental animals and observational studies in humans.
more